Novo Will Study Next-Generation Obesity Shot CagriSema in Kids

Novo Nordisk A/S is planning a large study of its next-generation obesity shot CagriSema in children, a sign the drugmaker is pressing forward with the compound despite disappointing results in other trials.

Set to start in January, the global study will recruit 460 children as young as 8 years old at 97 test centers across China, Europe and the Americas, according to a US government registry for clinical trials.

The step shows that Novo remains committed to CagriSema even after results have underwhelmed so far. It delivered lower-than-expected weight loss in a pair of high-profile studies of adults that were ...